Amneal Pharmaceuticals advances DHE autoinjector resubmission and secures FDA approval for exenatide
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), has achieved two significant milestones, reinforcing its position in the pharmaceutical industry. The company announced the resubmission of its New Drug Application (NDA) for a dihydroergotamine (DHE) prefilled syringe autoinjector for migraines and cluster headaches. At the same time, Amneal Pharmaceuticals received U.S. Food and Drug Administration (FDA) approval for […]